Efficacy of Colchicine and Budesonide in Improvement Outcomes of Patients with Coronavirus Infection 2019 in Damascus, Syria: A Randomized Control Trial

Table 1

Demographics and clinical characteristics.

Demographic/comorbidities		Supportive	Colchicine	Budesonide	value
Age (mean), years	18–40	ـــــ	ـــــ	ـــــ	ـــــ
	40–60	53	50	55	0.70
	60–80	69	60	67	0.67
	≥80	81	89	80	≤0.01
Gender	Male	9	5	5	0.87
	Female	12	9	9	0.87
Smoking	Nonsmoking	14	8	11	0.48
	Smoker	7	6	3	0.48
BMI	<30	8	5	5	0.98
	≥30	13	9	9	0.98
Kidney disease	None	10	10	10	0.06
	CKD	2	1	1	0.96
	AKI-1	3	2	1	0.79
	AKI-2	1	0	2	0.27
	AKI-3	1	1	0	0.62
	AKI on CKD	4	0	0	0.03
Cardiac disease	None	7	5	6	0.84
	HTN	10	6	7	0.92
	CHF	ـــــ	ـــــ	ـــــ	ـــــ
	Arrhythmia	0	0	1	0.14
	CAD	ـــــ	ـــــ	ـــــ	ـــــ
	Others	4	2	0	0.25
Endocrine disease	None	7	7	6	0.27
	Diabetes	14	7	5	0.25
	Others	0	0	3	0.09
Neurologic disease	None	15	12	12	0.47
	Stroke	2	0	0	0.36
	Others	4	2	2	0.32
Other diseases		2	4	0	0.06